NRXP Stock Risk & Deep Value Analysis
NRX Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About NRXP Stock
We analyzed NRX Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran NRXP through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
NRXP Risk Analysis & Red Flags
What Could Go Wrong
The company's critically precarious financial position and unsustainable reliance on dilutive capital raises could continue to erode shareholder value, even if NRX-101 proves clinically successful, making a 10x return on existing shares practically impossible due to share count explosion. A clinical trial failure would be catastrophic.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Chronic low cash reserves and high burn rate
- ⚠
History of highly dilutive capital raises
- ⚠
Past regulatory setbacks with ZYESAMI
- ⚠
Reliance on a single lead asset (NRX-101) for value creation
Upcoming Risk Events
- 📅
Negative or inconclusive NRX-101 clinical trial results
- 📅
Further highly dilutive equity raises
- 📅
Regulatory setbacks or delays for NRX-101
When to Reconsider
- 🚪
Negative or significantly delayed NRX-101 clinical trial results
- 🚪
Announcement of further large-scale, highly dilutive equity offerings without commensurate asset de-risking
- 🚪
Cash runway falls below 6 months without clear funding path
Unlock NRXP Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does NRX Pharmaceuticals Inc (NRXP) Do?
Sector
Healthcare
Industry
Biotechnology
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Visit NRX Pharmaceuticals Inc WebsiteInvestment Thesis
NRXP represents a high-risk, high-reward bet on the clinical and regulatory success of NRX-101 for Bipolar Depression with Suicidal Ideation, a significant unmet medical need. While the asset has compelling potential due to its Breakthrough Therapy designation, the company's severe financial fragility and consistent dilution pose substantial challenges to shareholder returns, necessitating extreme caution and a binary investment mindset.
Is NRXP Stock Undervalued?
Unlock the full AI analysis for NRXP
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
NRXP Price Targets & Strategy
12-Month Target
$5.50
Bull Case
$15.00
Bear Case
$0.50
Valuation Basis
Base target based on a successful clinical milestone for NRX-101, partially offsetting future dilution, valuing the asset at 0.1x of estimated peak sales potential ($500M-$1B range) by 2027.
Entry Strategy
High-risk entry: Consider small position only after a significant non-dilutive financing event or positive Phase 3 clinical trial readout for NRX-101. Avoid accumulating without clear progress on financial stability.
Exit Strategy
Take profit on significant spikes (e.g., +100-200% on major news). Implement a tight stop-loss below key technical support levels or if cash runway concerns intensify. Exit entirely on a failed clinical trial or inability to secure funding.
Portfolio Allocation
1-2% for aggressive risk tolerance only. This is a highly speculative, binary investment.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does NRXP Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding (if NRX-101 continues positive clinical progress) but highly fragile.
Moat Sources
1 Identified
The moat is dependent on successful clinical trials, robust patent protection for NRX-101, and the ability to differentiate from current and future treatments. It could be durable if NRX-101 gains market exclusivity and strong adoption.
Moat Erosion Risks
- •Clinical trial failure or inconclusive results for NRX-101
- •Patent challenges or expiration
- •Emergence of superior or more cost-effective competing therapies
- •Inability to commercialize effectively post-approval
NRXP Competitive Moat Analysis
Sign up to see competitive advantages
NRXP Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral with pockets of speculative bullishness tied to NRX-101's potential, often offset by bearish sentiment concerning dilution and financial instability.
Institutional Sentiment
Negative, primarily due to financial risk and dilution, leading to limited institutional participation beyond highly specialized biotech funds or those seeking deep value in distressed assets.
Insider Activity (Form 4)
Given frequent capital raises, historical insider activity likely involves both small opportunistic buys and necessary share sales/grants, but no consistent significant net buying signaling strong conviction appears evident from the general context. Will assume 'Normal activity' in absence of specific data.
Options Flow
Normal options activity; volumes are likely low and speculative, reflecting the highly binary nature of the company's prospects.
Earnings Intelligence
Next Earnings
Estimated early-May 2026
Surprise Probability
Low
Historical Earnings Pattern
Stock price typically reacts to cash runway updates, news regarding financing, and any clinical trial progress or setbacks, rather than traditional revenue/EPS beats/misses.
Key Metrics to Watch
Competitive Position
Top Competitor
Neurocrine Biosciences (NBIX)
Market Share Trend
Not applicable as a pre-commercial company. Future market share is entirely dependent on NRX-101 approval and commercialization.
Valuation vs Peers
NRXP trades at a significant discount to peers with approved CNS drugs or those in late-stage development with stronger balance sheets, primarily due to its early-stage pre-revenue status and severe financial constraints.
Competitive Advantages
- •Breakthrough Therapy designation for NRX-101
- •Targeting a significant unmet medical need (Bipolar Depression with Suicidal Ideation)
- •Potential for first-in-class treatment within its specific indication
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive NRXP Stock Higher?
Near-Term (0-6 months)
- •Update on NRX-101 Phase 3 clinical trial progress (timing and interim data, if applicable)
- •Announcement of a non-dilutive funding mechanism or strategic partnership
Medium-Term (6-18 months)
- •Top-line data readout from NRX-101 Phase 3 trial (potential Q4 2026 / Q1 2027)
- •Potential NDA (New Drug Application) submission for NRX-101 (post-successful Phase 3)
Long-Term (18+ months)
- •Potential FDA approval and commercial launch of NRX-101
- •Expansion of NRX-101 indications or development of pipeline assets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for NRXP?
- ✓
Positive Phase 3 data for NRX-101 and progression towards NDA submission
- ✓
Successful execution of non-dilutive financing or significant partnership
- ✓
Improvement in cash runway and reduction in quarterly burn rate
Bull Case Analysis
See what could go right with Premium
Competing with NRXP
See how NRX Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
NRX Pharmaceuticals Inc NRXP | — | 3.0 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for NRX Pharmaceuticals Inc (NRXP)?
As of March 27, 2026, NRX Pharmaceuticals Inc has a DVR Score of 3.0 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does NRX Pharmaceuticals Inc use?
NRXP is the ticker symbol for NRX Pharmaceuticals Inc. The company trades on the NCM.
What is the risk level for NRXP stock?
Our analysis rates NRX Pharmaceuticals Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the NRXP DVR analysis updated?
Our AI-powered analysis of NRX Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 27, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for NRXP (NRX Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.